doi: 10.1093/humrep/del261 27
For instance, in the case of advanced/metastatic non-small cell lung cancer (NSCLC) with METex14, GEOMETRY mono-1, a multicenter, open-label, multicohort phase 2 trial, demonstrated that capmatinib was highly effective against tumors in patients with advanced or metastatic NSCLC at stages IIIB and IV, particularly those with METex14 or MET amplification, especially in settings without prior treatment [27]
High-strength retinoids
Examples from related peptide use indicate cautious low-dose trials under supervision, not routine high-dose supplementation
Follow-Up and Guidance: Staff provide post-treatment care instructions and wellness advice
This assetization reinforces TOD as a developmental paradigm, reshaping urban governance in speculative yet institutionalized ways